Description
Anti-IL17 Antibody, Non-Fucosylated (BioBet-288ZP) is a human monoclonal IgG1, κ antibody against IL17. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Multiple sclerosis (MS)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL17 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL17
Alternative Names
IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)
Gene ID
3605
UniProt ID
Q16552
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL17A include Arthritis and Bronchiolitis Obliterans.
Related Pathways
Its related pathways are PEDF Induced Signaling and Immune response IL-23 signaling pathway.
Function
Ligand for IL17RA and IL17RC. The heterodimer formed by IL17A and IL17F is the ligand of the heterodimer formed by IL17RA and IL17R. Participate in inducing stromal cells to produce pro-inflammatory and hematopoietic cytokines.
Field of research
Cancer antibody; Immune System antibody
Post-translational modifications
Found both in glycosylated and nonglycosylated forms
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-288ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL17. Afasevikumab is a human monoclonal antibody that can be potentially used in the treatment of Multiple sclerosis (MS).
Antibody Indication
Multiple sclerosis (MS)
